TargetBeta
CCR8
C-C motif chemokine receptor 8 · also CY6, TER1, CKR-L1, GPR-CY6 · CD molecules
7 programs in company-led studies act on CCR8, from 7 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 75 running | – | the company's pipeline |
| denikitugrule | Gilead Sciences | phase 2 | 33 running | – | NCIt |
| imzokitug | Bristol-Myers Squibb | phase 2 | 22 running | – | a judged reading |
| CCR8 Inhibitor IPG7236rule | Nanjing Immunophage Biotech | phase 2 | 31 running | – | NCIt |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 11 running | – | NCIt |
| Anti-CCR8 Monoclonal Antibody HC006rule | HC Biopharma | phase 1 | 22 running | – | NCIt |
| azirkitug | AbbVie | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 2 programs
- Adenocarcinoma Of Esophagus, 1 program
- Colorectal Neoplasms, 1 program
- Dermatitis, Atopic, 1 program
- Pancreatic Neoplasms, 1 program
- Uterine Cervical Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jul 2027azirkitug · AbbVie · phase 1 · NCT05005403
- Dec 2027cafelkibart · Sino Biopharmaceutical · phase 3 · NCT06821503
- Sep 15, 2028imzokitug · Bristol-Myers Squibb · phase 2 · NCT07680764
- Dec 2028denikitug · Gilead Sciences · phase 2 · NCT07527858
- Dec 26, 2028Anti-CCR8 Antibody-drug Conjugate TAK-188 · Takeda · phase 2 · NCT07205718
- Dec 30, 2028CCR8 Inhibitor IPG7236 · Nanjing Immunophage Biotech · phase 2 · NCT07508761
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.